A hormone secreted into the blood during endurance, or aerobic, exercise reduces levels of a protein linked to Parkinson’s disease and halts movement problems in mice, researchers report.
Parkinson’s disease, a neurologic condition that causes people to lose control over their muscles and movements, affects about 1 million people in the US.
If confirmed in additional laboratory research and clinical trials, the researchers’ study in mice engineered to have Parkinson’s disease symptoms could pave the way for a Parkinson’s disease therapy based on the hormone irisin.
“If irisin’s utility pans out, we could envision it being developed into a gene or recombinant protein therapy.”
Johns Hopkins Medicine’s Ted Dawson, and the Dana Farber Cancer Institute’s Bruce Spiegelman worked together to look into the link between the exercise molecule irisin and Parkinson’s disease.
For unknown reasons, endurance exercise has long been found to alleviate symptoms of Parkinson’s disease. Dawson, whose research focuses on neurodegenerative diseases, including Parkinson’s disease, says one of the first clues to the link between exercise, Parkinson’s disease, and irisin came from Spiegelman, whose first paper about irisin was published in 2012 in Nature and subsequently in other scientific journals, showing that a protein called an irisin peptide is released into the blood and increases with endurance exercise.
In the past decade, other laboratories have found that exercise elevates levels of irisin, and there is interest in looking into the connection between irisin and Alzheimer’s disease as well as Parkinson’s disease.
To test the effects of irisin on Parkinson’s disease, Dawson and Spiegelman’s teams began with a research model used by Dawson in which mouse brain cells are engineered to spread small, spindly fibers of alpha synuclein, a protein that regulates moods and movements related to the brain neurotransmitter dopamine.
When alpha synuclein proteins clump, those clusters kill dopamine-producing brain cells, a key trigger of Parkinson’s disease. Fibrous clumps of alpha synuclein are very similar, says Dawson, to what is found in the brains of people with Parkinson’s disease.
In the laboratory model, the researchers found that irisin prevented the accumulation of alpha synuclein clumps and its associated brain cell death.
Next, the research teams tested irisin’s effects on mice engineered to have Parkinson’s-like symptoms. They injected alpha synuclein into an area of the mouse brain, called the striatum, where dopamine-producing neurons extend. Two weeks later, the researchers injected a viral vector, which increased blood levels of irisin, which can cross the blood-brain barrier, into the mice.
Six months later, mice that received irisin had no muscle movement deficits, while those injected with a placebo showed deficits in grip strength and their ability to descend a pole.
The researchers demonstrated that irisin also speeds up the transport and degradation of alpha synuclein via fluid-filled sacs called lysosomes in brain cells.
“If irisin’s utility pans out, we could envision it being developed into a gene or recombinant protein therapy,” says Dawson, referring to the widening field of drug development aimed at using cellular genetics to treat disease. Dawson is a professor in neurodegenerative diseases, a professor of neurology, and director of the Johns Hopkins Institute for Cell Engineering.
“Given that irisin is a naturally produced peptide hormone and seems to have evolved to cross the blood brain-barrier, we think it is worth continuing to evaluate irisin as a potential therapy for Parkinson’s and other forms of neurodegeneration” adds Spiegelman.
Dawson and Spiegelman have filed for patents on the use of irisin in Parkinson’s disease. Spiegelman has created a biotechnology company, Aevum Therapeutics Inc., based in Boston, to develop irisin into treatments for neurodegenerative disease.
Results of the researchers’ tests appear in the Proceedings of the National Academy of Sciences.
Additional scientists who contributed to the research are from Johns Hopkins and Harvard Medical School.
Funding for the research came from the JPB Foundation, the Maryland Stem Cell Research Fund, the Mark Foundation for Cancer Research, the Damon Runyon Cancer Research Foundation, and Deutsche Forschungsgemeinschaft.
Source: Johns Hopkins University
